Patients with rheumatoid arthritis achieving clinical deep remission (CliDR) maintain long-term remission better than those meeting less stringent criteria.
2
In a study of 145 patients, 63% in the CliDR group maintained sustained remission at 5 years, compared to 38% in the non-CliDR group.
3
Relapse rates were significantly lower in the CliDR group, with only 12 relapses compared to 70 in the non-CliDR group.
4
Tapering treatment increased relapse risk 8.5-fold in non-CliDR patients, while the risk was significantly lower in the CliDR group.
5
The study highlights that deeper remission may offer better prognostic information for treatment tapering decisions in rheumatoid arthritis.
